Fig. 6

In vivo therapeutic efficacy of CussOMEp (300 µg per mouse) combined with αPD-1 (1 mg/kg) in an abscopal tumor model. (a) Schematic representation of the treatment schedule. (b, c) Growth curves of primary tumors, presented as total (b) and individual sizes (c), n = 8. (d, e) Growth curves of distant tumors, shown as total (d) and individual sizes (e). (f-i) Percentages of DC maturation (f), M2 macrophages (g), M1 macrophages (h), and Tregs (i). (j-m) Statistical analysis of immune cell populations, including CD4⁺ T cells (j), CD8⁺ T cells (k), CD8⁺IFN-γ⁺ T cells (l), and effector T cells (m). Statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, determined by one-way ANOVA followed by Dunnett’s multiple comparisons test. Data are presented as mean ± s.d